Vericel (VCEL) opened Q1 2026 with total revenue of US$68.4 million and a basic EPS loss of US$0.12, setting a clear focal point for how the market reads its latest update. Over recent periods the company has seen revenue move from US$52.6 million in Q1 2025 to US$68.4 million in Q1 2026, while basic EPS shifted from a loss of US$0.23 to a smaller loss of US$0.12, giving investors a clean read on how top line scale and earnings per share are tracking into this new quarter. Against that backdrop, investors are likely to focus on how margins are holding up as the business balances growth with profitability.

See our full analysis for Vericel.

With the headline numbers on the table, the next step is to set these results against the widely held narratives about Vericel to see which storylines the latest margins and earnings trends support and which ones they call into question.

Trailing 12‑month earnings turn positive

• Over the last 12 months, Vericel generated total revenue of US$292.1 million and net income of US$21.5 million, which equates to basic EPS of US$0.42 and a net margin of 7.3% versus 1.2% a year earlier.
• What stands out against the bullish narrative is that this profitable trailing picture sits next to a single quarter loss in Q1 2026, which bulls argue is a short term bump in a longer earnings ramp, while:
  • Q1 2026 basic EPS was a loss of US$0.12 compared with positive EPS of US$0.46 in Q4 2025, even though the trailing trend shows multi year earnings growth of about 45.6% per year.
  • Bulls also point to forecasts for roughly 33.3% yearly earnings growth and 14.6% yearly revenue growth as a reason to focus more on the 7.3% trailing margin than on one quarter of loss making EPS.

Over the last year, bulls say MACI expansion and Burn Care growth can keep pushing profitability higher. This mix of a profitable 12 month record with a soft Q1 is exactly what they watch for when judging if the long term story is intact 🐂 Vericel Bull Case.

Premium P/E and DCF gap

• Vericel is trading on a P/E of 83.4x and a current share price of US$35.13, compared with a DCF fair value of US$8.53 and an analyst consensus price target of US$54.57.
• Bears highlight this valuation stretch as a key concern, arguing that even with strong earnings growth the current price already bakes in a lot of good news, and the numbers give them a few talking points:
  • The 83.4x P/E sits far above the US Biotechs industry average of 17.8x and a peer average of 16.4x, so on simple earnings multiples the stock screens as expensive.
  • The DCF fair value of US$8.53 is well below both the US$35.13 share price and the US$54.57 analyst target, which bears see as a sign that cash flow based models do not line up with the more optimistic earnings based expectations.

Skeptics lean heavily on this gap between an 83.4x P/E, the DCF fair value and the analyst target when they argue the stock carries rich expectations 🐻 Vericel Bear Case.

Q1 loss versus prior profitable quarters

• Q1 2026 net income was a loss of US$6.3 million on revenue of US$68.4 million, compared with net income of US$23.2 million on US$92.9 million of revenue in Q4 2025 and US$5.1 million on US$67.5 million of revenue in Q3 2025.
• The consensus narrative frames this as part of a broader growth story backed by expanding surgeon networks and product penetration, yet the recent loss puts some practical questions in front of investors:
  • Analysts looking for revenue to grow about 23.5% annually and profit margins to move from 2.9% to 16.2% over three years now have to square those forecasts with a quarter that returned to loss making territory.
  • At the same time, the trailing 12 month EPS of US$0.42 and net income of US$21.5 million show that the business has been profitable over a longer window, which supports the idea that single quarter swings can occur even when the multi year margin trend is improving.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Vericel on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With bulls, bears, and consensus voices all weighing in, it helps to see the numbers for yourself and decide where you stand. If you want a quick snapshot of what investors are optimistic about, start by checking the 3 key rewards

See What Else Is Out There

Vericel combines a recent quarterly loss with an 83.4x P/E and a DCF fair value far below its share price, which raises valuation concerns.

If that kind of rich pricing makes you uneasy, it is worth checking stocks that currently screen as more attractively priced via the 51 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.